Original Articles

Evaluation cut-off point of Prostate-Specific Antigen (PSA) and Prostate-Specific Antigen (PSA)-density in prostate cancer suspected patients at Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia

Moch Ilfan Gunadi , Muhammad Asykar Palinrungi, Khoirul Kholis, Syakri Syahrir, Syarif Syarif, Arifin Seweng

Moch Ilfan Gunadi
Department of Surgery, Faculty of Medicine, Universitas Hassanudin, Makassar, Indonesia.. Email: ilfangunadi@gmail.com

Muhammad Asykar Palinrungi
Division of Urology, Department of Surgery, Faculty of Medicine, Universitas Hassanudin, Makassar, Indonesia.

Khoirul Kholis
Division of Urology, Department of Surgery, Faculty of Medicine, Universitas Hassanudin, Makassar, Indonesia.

Syakri Syahrir
Division of Urology, Department of Surgery, Faculty of Medicine, Universitas Hassanudin, Makassar, Indonesia.

Syarif Syarif
Division of Urology, Department of Surgery, Faculty of Medicine, Universitas Hassanudin, Makassar, Indonesia.

Arifin Seweng
Department of Public Health, Faculty of Medicine, Universitas Hassanudin, Makassar, Indonesia
Online First: December 13, 2020 | Cite this Article
Gunadi, M., Palinrungi, M., Kholis, K., Syahrir, S., Syarif, S., Seweng, A. 2020. Evaluation cut-off point of Prostate-Specific Antigen (PSA) and Prostate-Specific Antigen (PSA)-density in prostate cancer suspected patients at Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia. Indonesia Journal of Biomedical Science 15(1): 8-12. DOI:10.15562/ijbs.v15i1.248


Background: PSA is a test performed to detect prostate cancer. There is currently no rational standard for its cut-off point, resulting in the increasing number of patients with prostate biopsy complications. This study aims to determine the estimated cut-off point of PSA and PSAD among patients with suspected prostate cancer (PCa) in Makassar.

Methods: A single-center retrospective analysis using a cross-sectional design was applied in this research. The sample was obtained through medical record data from benign prostate enlargement (BPE) and PCa patients in three affiliate hospitals from January 2014 to December 2019. Mann-Whitney U, Chi-Square, Fisher's Exact, and ROC tests were performed in the statistical analysis (considered significant if p <0.05). Data were analyzed using SPSS version 22 for Windows.

Results: Among 470 subjects, 88.3% were BPE patients, and 11.7% were PCa. Lower urinary tract symptoms (LUTS) were found in 70.6% of patients, and those with hematuria remained at 10.6%. The average prostate volume was 53.8±25.72 ml. The prostate consistency examination with the digital rectal examination (DRE) made up 84.3% Solid Chewy in the BPE sample and 96.4% hard solid in the PCa sample. The average PSA value in BPE was 14.82±20.1 ng/ml, and the PCa was 48.10±42.58 ng/ml, while the average PSAd BPE value was 0.287±0.40 ng/ml, and PCa was 1.19±1.32 ng/ml. PSA cut-off point was 18.62 ng/ml. PSAD cut-off point was 0.533.

Conclusion: PSA and PSAD cut-off points in this study 18.62 ng/ml and 0.533. The cut-off point obtained is far higher than the value agreed upon in advance.

References

Dunn MW, Kazer MW. Prostate cancer overview. Semin Oncol Nurs. 2011;27(4):241-250.

Simanjuntak DTM, Safriadi F. Cut-off point of PSA and PSA density in prostate cancer suspected patients. Indonesian Journal of Urology. 2016;23(1):1-6.

Teoh JY, Yuen SK, Tsu JH, Wong CW, Ho BS, Ng AT, et al. The performance characteristics of prostate-specific antigen and prostate-specific antigen density in Chinese men. Asian J Androl. 2017;19(1):113-116.

Siswandi A, Sahara N, Efanto A. Gambaran Klinis Kanker Prostat dan Benign Prostate Hyperplasia (BPH) pada Pasien Retensi Urin di RSUD Dr. H Abdul Moeloek- Bandar Lampung tahun 2015. Jurnal Ilmu Kedokteran dan Kesehatan. 2015;2(2):1–10.

Capogrosso P, Capitanio U, Vertosick EA, Ventimiglia E, Chierigo F, Oreggia D, et al. Temporal Trend in Incidental Prostate Cancer Detection at Surgery for Benign Prostatic Hyperplasia. Urology. 2018;122:152-157.

Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. 2017;4(3):148-151.

Rasul G, Khan I, Jan MA, Ahmad T, Khattak IU, Aslam M. Frequency of incidental prostate cancer in patients presenting with palpable enlarged prostate gland. J Postgrad Med Inst. 2019;33(3):5-210.

Ramos NL, Dzung DT, Stopsack K, Janko V, Pourshafie MR, Katouli M, et al. Characterisation of uropathogenic Escherichia coli from children with urinary tract infection in different countries. Eur J Clin Microbiol Infect Dis. 2011;30(12):1587-1593.

Putra IB, Hamid AR, Mochtar CA, Umbas R. Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia. Prostate Int. 2016;4(2):43-48.

Merriel SWD, Funston G, Hamilton W. Prostate Cancer in Primary Care. Adv Ther. 2018;35(9):1285-1294.

Chen JW, Shin JH, Tsao TF, Ko HG, Yoon HK, Han KC, et al. Prostatic Arterial Embolization for Control of Hematuria in Patients with Advanced Prostate Cancer. J Vasc Interv Radiol. 2017;28(2):295-301.

Sausville J, Naslund M. Benign prostatic hyperplasia and prostate cancer: an overview for primary care physicians. Int J Clin Pract. 2010;64(13):1740-1745.

Gandaglia G, Zaffuto E, Fossati N, Cucchiara V, Mirone V, Montorsi F, et al. The role of prostatic inflammation in the development and progression of benign and malignant diseases. Curr Opin Urol. 2017;27(2):99-106.

Rehman AU, Khattak IU, Jan MA, Ahmad B. Caveats of Prostate Cancer Diagnosis: Diagnostic Utility Study Of Digital Rectal Examination, Prostate Volume And Prostate Specific Antigen. J Postgrad Med Inst. 2018;32(2):5-211.

Aminsharifi A, Howard L, Wu Y, Hoedt AD, Bailey C, Freedland SJ, et al. Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index. J Urol. 2018;200(4):758-766.

Khalil S, de Riese W. Association of benign prostatic hyperplasia (BPH) volume and prostate cancer: consecutive data from an academic institution in respect to the current scientific view. World J Urol. 2017;35(10):1633-1634.

Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63–89.

Rosita L, Occifa GA. Analysis of Prostate Specific Antigen (PSA) level on Medical Check-up (MCU) Participants. Bali Medical Journal. 2019;8(1):267-269.

Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008;15(1):3866-3871.

Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol. 2018;25(6):524-531.

Mochtar CA, Atmoko W, Umbas R, Hamid ARAH. Prostate cancer detection rate in Indonesian men. Asian J Surg. 2018;41(2):163-169.

Putra PCA, Umbas R, Hamid ARAH, Mochtar CA. Age, prostate volume, prostate-specific antigen and prostate-specific antigen density as predictor factors in results of transrectal ultrasonography-guided prostate biopsy. F1000Research. 2019;8:1-10

Hsiao CJ, Tzai TS, Chen CH, Yang WH, Chen CH. Analysis of Urinary Prostate-Specific Antigen Glycoforms in Samples of Prostate Cancer and Benign Prostate Hyperplasia. Dis Markers. 2016;2016:8915809.


No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0